Fosrenol Approved In Higher Dose Formulation
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has approved a higher dose formulation for the end-stage renal disease agent Fosrenol (lanthanum), Shire announced Nov. 28
You may also be interested in...
FDA Warns Novartis, Shire On Misbranding
Shire pulls Fosrenol promos, calling them an “an unfortunate error.”
FDA Warns Novartis, Shire On Misbranding
Shire pulls Fosrenol promos, calling them an “an unfortunate error.”
Shire's Fosrenol Is Boosting ESRD Market, Not Switching Renagel Patients, Genzyme Says
Renagel remains healthy despite competition from Shire's phosphate-control agent, the company maintains. Genzyme continues to see opportunities for its end-stage renal disease therapy with Medicare Part D.